Innorna, a Hong Kong-based clinical-stage biotech company advancing RNA medicines, announced on Thursday that it has been nominated for the 2026 Prix Galien USA Best Startup Award.

Innorna was shortlisted in the Best Startup category, reflecting the innovation in its mRNA-LNP platform and a clinical pipeline that has advanced beyond vaccines into therapeutics. The company's lead program, IN026, is a novel mRNA therapy for refractory gout, designed to reduce uric acid. It received FDA IND clearance in March 2026, extending mRNA-based protein replacement into common chronic disease.

The Prix Galien is claimed to honour extraordinary achievements in medical innovation that improve human health. Winners are selected by committees of leading biomedical scientists, industry executives, and Nobel Laureates from around the world.